Tribovax Vet. injektionsvæske, suspension Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

tribovax vet. injektionsvæske, suspension

intervet international b.v. - clostridium botulinum, type a toxin-haemagglutinin compleks, clostridium chauvoei, stamme cn 3796 (inaktiveret), clostridium novyi type b alfa toxoid, clostridium perfringens type a, alpha toxoid, clostridium perfringens type b og c, beta toxoid, clostridium perfringens type d, epsilon toxoid, clostridium septicum toxoid, clostridium sordellii toxoid, clostridium tetani, toxoid - injektionsvæske, suspension

Tabrecta Den Europæiske Union - dansk - EMA (European Medicines Agency)

tabrecta

novartis europharm limited  - capmatinib dihydrochloride monohydrate - carcinom, ikke-småcellet lunge - antineoplastiske midler - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Orserdu Den Europæiske Union - dansk - EMA (European Medicines Agency)

orserdu

stemline therapeutics b.v. - elacestrant - bryst neoplasmer - endokrine terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Vanflyta Den Europæiske Union - dansk - EMA (European Medicines Agency)

vanflyta

daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukæmi, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.